WuXi PharmaTech Announces Fourth Quarter and Full Year 20...(our laboratory servicesand research manu...)

"We remain focused on our goal to transform the drug R&D model globally. An important milestone towards reaching that goal was our recent acquisition of US-based AppTec Laboratory Services Inc., providing us with new capabilities in biologics and medical device testing and manufacturing as well as an expanded geographic footprint. Our integration efforts are ongoing, and by offering a broader range of complementary capabilities across the globe, we are well positioned to drive long-term growth and create value for our customers and shareholders."

Fourth Quarter and Full Year 2007 Unaudited Financial Results

Net Revenues. Net revenues increased 62.4% to $37.1 million in the fourth quarter 2007 from $22.8 million for the fourth quarter 2006. Net revenues from laboratory services increased 33.1% to $28.8 million in the fourth quarter 2007 from $21.7 million in the fourth quarter 2006. The increase was primarily driven by continued strong growth across our core services including discovery chemistry, process research and bioanalytical services. Net revenues from research manufacturing increased by 603.9% to $8.3 million in the fourth quarter 2007 from $1.1 million in the fourth quarter 2006, primarily attributable to an increase in the number and scope of projects.

Net revenues for the full year 2007 increased 93.3% to $135.2 million from $69.9 million in 2006. Laboratory services revenues grew 71.3% to $102.4 million while research manufacturing revenues increased 222.9% to $32.8 million. The growth in net revenues for the full year 2007 is attributable to an increase in business volume for both laboratory services and research manufacturing. Our ongoing commitment to high quality customer service resulted in a
'/>"/>